0001209191-21-008229.txt : 20210205 0001209191-21-008229.hdr.sgml : 20210205 20210205174924 ACCESSION NUMBER: 0001209191-21-008229 CONFORMED SUBMISSION TYPE: 5 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galante Joseph C CENTRAL INDEX KEY: 0001632384 FILING VALUES: FORM TYPE: 5 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 21597577 MAIL ADDRESS: STREET 1: 111 TENTH AVENUE STREET 2: SUITE 200 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 5 1 doc5.xml FORM 5 SUBMISSION X0306 5 2020-12-31 0 0 1 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001632384 Galante Joseph C 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203 1 0 0 0 Common Stock 2020-08-27 4 L 0 75 3.28 A 24967 D Common Stock 2020-08-28 4 L 0 75 3.24 A 25042 D Common Stock 2020-08-31 4 L 0 75 3.25 A 25117 D Common Stock 2020-09-01 4 L 0 75 3.24 A 25192 D Common Stock 2020-09-02 4 L 0 75 3.32 A 25267 D Common Stock 2020-09-03 4 L 0 75 3.35 A 25342 D Common Stock 2020-09-04 4 L 0 75 3.29 A 25417 D Common Stock 2020-09-08 4 L 0 75 3.22 A 25492 D Common Stock 2020-09-09 4 L 0 75 3.28 A 25567 D Common Stock 2020-09-10 4 L 0 75 3.34 A 25642 D Common Stock 2020-09-11 4 L 0 75 3.36 A 25717 D Common Stock 2020-09-14 4 L 0 75 3.41 A 25792 D Common Stock 2020-09-15 4 L 0 75 3.41 A 25867 D Common Stock 2020-09-16 4 L 0 75 3.41 A 25942 D Common Stock 2020-09-17 4 L 0 75 3.41 A 26017 D Common Stock 2020-09-18 4 L 0 75 3.41 A 26092 D Common Stock 2020-09-21 4 L 0 75 3.37 A 26167 D Common Stock 2020-09-22 4 L 0 75 3.36 A 26242 D Common Stock 2020-09-23 4 L 0 75 3.31 A 26317 D Common Stock 2020-09-24 4 L 0 75 3.19 A 26392 D Common Stock 2020-09-25 4 L 0 75 3.31 A 26467 D Common Stock 2020-09-28 4 L 0 75 3.27 A 26542 D Common Stock 2020-09-29 4 L 0 75 3.26 A 26617 D Common Stock 2020-09-30 4 L 0 75 3.26 A 26692 D Common Stock 2020-10-01 4 L 0 75 3.29 A 26767 D Common Stock 2020-10-02 4 L 0 75 3.33 A 26842 D Common Stock 2020-10-05 4 L 0 75 3.35 A 26917 D Common Stock 2020-10-06 4 L 0 75 3.35 A 26992 D Common Stock 2020-10-07 4 L 0 75 3.24 A 27067 D Common Stock 2020-10-08 4 L 0 75 3.24 A 27142 D The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020. Filing 1 of 3 Joseph C. Galante by /s/ Michael Bonner as attorney-in-fact 2021-02-05